Bottom line
SHPCX vs FBDIX: the short answer
SHPCX (Health & Biotechnology Portfolio) and FBDIX (Franklin Biotechnology Discovery Fund) are both mutual funds.
But FBDIX is far broader, holding 126 positions to 29 for SHPCX, so beyond the top names it adds exposure SHPCX doesn't have.
FBDIX is cheaper at 1.01% vs 3.6% — a difference of $259 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +3.7% for SHPCX (reporting dates differ).
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
SHPCX vs FBDIX side by side
| SHPCX | FBDIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Saratoga Advantage | Franklin Templeton |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 3.6% | 1.01% |
| Annual cost per $10k | $360 | $101 |
| 10-yr cost on $10k (prospectus) | $3,862 | $1,728 |
| Max front load | 0% | 5.5% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | −1.3% | +43.9% |
| 5-yr return (annualized) | +3.7% | +5.0% |
| 10-yr return (annualized) | +4.1% | +6.4% |
| Best quarter | +15.0% | +29.5% |
| Worst quarter | −13.0% | −24.5% |
| Net assets (fund) | $10.5M | $1.2B |
| Number of holdings | 29 | 126 |
| Portfolio turnover | 22% | 38% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHPCX | FBDIX | Difference |
|---|---|---|---|
| 2024 | −0.3% | +4.0% | −4.3% |
| 2023 | −0.9% | +18.4% | −19.3% |
| 2022 | +1.4% | −12.7% | +14.1% |
| 2021 | +16.0% | −17.7% | +33.7% |
| 2020 | +3.0% | +29.9% | −26.9% |
| 2019 | +15.4% | +34.8% | −19.4% |
| 2018 | −6.0% | −15.7% | +9.7% |
| 2017 | +11.3% | +18.8% | −7.6% |
| 2016 | −2.5% | −17.2% | +14.7% |
| 2015 | +6.3% | +5.5% | +0.8% |
Source: Fund prospectus bar charts
Holdings overlap
5 of SHPCX's top 25 holdings also appear in FBDIX's top 25.
| Holding | SHPCX | FBDIX |
|---|---|---|
| Amgen Inc | 5.04% | 4.39% |
| Gilead Sciences Inc | 3.94% | 3.86% |
| Regeneron Pharmaceuticals Inc | 3.93% | 3.77% |
| Vertex Pharmaceuticals Inc | 3.36% | 3.54% |
| Eli Lilly & Company | 2.11% | 1.31% |
Source: SEC Form N-PORT
SHPCX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
FAQ
What is the difference between SHPCX and FBDIX?
Which is cheaper, SHPCX or FBDIX?
Should I own both SHPCX and FBDIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.